Characterization of Cytomegalovirus Disease in Solid Organ Transplant Recipients by Markers of Inflammation in Plasma

PLoS ONE

Volumn 8, Issue 4, 2013, Pages

  Rollag, Halvor ^a,c   Ueland, Thor ^a   Åsberg, Anders ^b   Hartmann, Anders ^a,c   Jardine, Alan G ^d   Humar, Atul ^e   Pescovitz, Mark D ^f   Bignamini, Angelo A ^g   Aukrust, Pål ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d UNIVERSITY OF GLASGOW   (United Kingdom)

^e UNIVERSITY OF ALBERTA   (Canada)

^f INDIANA UNIVERSITY   (United States)

^g UNIVERSITY OF MILAN   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTACOID; C REACTIVE PROTEIN; CXCL16 CHEMOKINE; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GANCICLOVIR; IMMUNOSUPPRESSIVE AGENT; PENTRAXIN 3; RANTES; SECONDARY LYMPHOID TISSUE CHEMOKINE; TUMOR NECROSIS FACTOR RECEPTOR 1; VALGANCICLOVIR; VIRUS DNA; VON WILLEBRAND FACTOR;

ADULT; ARTICLE; CELL ACTIVATION; CLINICAL FEATURE; CONTROLLED CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; ENDOTHELIUM CELL; ENZYME IMMUNOASSAY; FEMALE; GRAFT RECIPIENT; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY (TOPIC); ORGAN TRANSPLANTATION; POST HOC ANALYSIS; PROTEIN BLOOD LEVEL; VIRUS LOAD;

ADULT; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CHEMOKINES; CYTOMEGALOVIRUS; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; TRANSPLANTS;

CYTOMEGALOVIRUS;

EID: 84876004102     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0060767     Document Type: Article

References (28)

1. Sagedal S, Nordal KP, Hartmann A, Degre M, Holter E, et al. (2000) A prospective study of the natural course of cytomegalovirus infection and disease in renal allograft recipients. Transplantation 70: 1166-74.
2. Asberg A, Humar A, Rollag H, Jardine AG, Mouas H, et al. (2007) Oral valganciclovir is noninferior to intravenous ganciclovir for the treatment of cytomegalovirus disease in solid organ transplant recipients. Am J Transplant 7: 2106-2113.
3. Hummel M, Abecassis MM, (2002) A model for reactivation of CMV from latency. J Clin Virol 25Suppl 2: S123-S136.
4. Bodaghi B, Jones TR, Zipeto D, Vita C, Sun L, et al. (1998) Chemokine sequestration by viral chemoreceptors as a novel viral escape strategy: withdrawal of chemokines from the environment of cytomegalovirus-infected cells. J Exp Med 188: 855-866.
5. Chang WL, Baumgarth N, Yu D, Barry PA, (2004) Human cytomegalovirus-encoded interleukin-10 homolog inhibits maturation of dendritic cells and alters their functionality. J Virol 78: 8720-8731.
6. Humar A, St Louis P, Mazzulli T, McGeer A, Lipton J, et al. (1999) Elevated serum cytokines are associated with cytomegalovirus infection and disease in bone marrow transplant recipients. J Infect Dis 179: 484-488.
7. Rollag H, Åsberg A, Ueland T, Hartmann A, Jardine AG, et al. (2012) Treatment of cytomegalovirus disease in solid organ transplant recipients; markers of inflammation as predictors of outcome. Transplantation 94: 1060-1065.
8. Asberg A, Humar A, Jardine AG, Rollag H, Pescovitz MD, et al. (2009) Long-term outcomes of CMV disease treatment with valganciclovir versus IV ganciclovir in solid organ transplant recipients. Am J Transplant 9: 1205-1213.
9. Kotton CN, Kumar D, Caliendo AM, Asberg A, Chou S, et al. (2010) International consensus guidelines on the management of cytomegalovirus in solid organ transplantation. Transplantation 89: 779-795.
10. Preiksaitis JK, Brennan DC, Fishman J, Allen U, (2005) Canadian society of transplantation consensus workshop on cytomegalovirus management in solid organ transplantation final report. Am J Transplant 5: 218-227.
11. Manuel O, Asberg A, Pang X, Rollag H, Emery VC, et al. (2009) Impact of genetic polymorphisms in cytomegalovirus glycoprotein B on outcomes in solid-organ transplant recipients with cytomegalovirus disease. Clin Infect Dis 49: 1160-1166.
12. Humar A, Asberg A, Kumar D, Hartmann A, Moussa G, et al. (2009) An assessment of herpesvirus co-infections in patients with CMV disease: correlation with clinical and virologic outcomes. Am J Transplant 9: 374-381.
13. Bollerslev J, Ueland T, Jorgensen AP, Fougner KJ, Wergeland R, et al. (2006) Positive effects of a physiological dose of GH on markers of atherogenesis: a placebo-controlled study in patients with adult-onset GH deficiency. Eur J Endocrinol 154: 537-543.
14. Cheeran MC, Hu S, Sheng WS, Peterson PK, Lokensgard JR, (2003) CXCL10 production from cytomegalovirus-stimulated microglia is regulated by both human and viral interleukin-10. J Virol 77: 4502-4515.
15. Lazzeri E, Romagnani P, (2005) CXCR3-binding chemokines: novel multifunctional therapeutic targets. Curr Drug Targets Immune Endocr Metabol Disord 5: 109-118.
16. Wenzel J, Tuting T, (2008) An IFN-associated cytotoxic cellular immune response against viral, self-, or tumor antigens is a common pathogenetic feature in "interface dermatitis". J Invest Dermatol 128: 2392-2402.
17. Hokeness KL, Deweerd ES, Munks MW, Lewis CA, Gladue RP, et al. (2007) CXCR3-dependent recruitment of antigen-specific T lymphocytes to the liver during murine cytomegalovirus infection. J Virol 81: 1241-1250.
18. Sumino KC, Walter MJ, Mikols CL, Thompson SA, Gaudreault-Keener M, et al. (2010) Detection of respiratory viruses and the associated chemokine responses in serious acute respiratory illness. Thorax 65: 639-644.
19. Casrouge A, Decalf J, Ahloulay M, Lababidi C, Mansour H, et al. (2011) Evidence for an antagonist form of the chemokine CXCL10 in patients chronically infected with HCV. J Clin Invest 121: 308-317.
20. Cinque P, Bestetti A, Marenzi R, Sala S, Gisslen M, et al. (2005) Cerebrospinal fluid interferon-gamma-inducible protein 10 (IP-10, CXCL10) in HIV-1 infection. J Neuroimmunol 168: 154-163.
21. Deban L, Jaillon S, Garlanda C, Bottazzi B, Mantovani A, (2011) Pentraxins in innate immunity: lessons from PTX3. Cell Tissue Res 343: 237-249.
22. Bozza S, Bistoni F, Gaziano R, Pitzurra L, Zelante T, et al. (2006) Pentraxin 3 protects from MCMV infection and reactivation through TLR sensing pathways leading to IRF3 activation. Blood 108: 3387-3396.
23. D'Angelo C, De Luca A, Zelante T, Bonifazi P, Moretti S, et al. (2009) Exogenous pentraxin 3 restores antifungal resistance and restrains inflammation in murine chronic granulomatous disease. J Immunol 183: 4609-4618.
24. van Leeuwen EM, van Buul JD, Remmerswaal EB, Hordijk PL, ten Berge U, et al. (2005) Functional re-expression of CCR7 on CMV-specific CD8+ T cells upon antigenic stimulation. Int Immunol 17: 7137-7139.
25. Marsland BJ, Battig P, Bauer M, Ruedl C, Lassing U, et al. (2005) CCL19 and CCL21 induce a potent proinflammatory differentiation program in licensed dendritic cell. Immunity 22: 493-505.
26. Middel P, Raddatz D, Gunawan B, Haller F, Radzun HJ, (2006) Increased number of mature dendritic cells in Crohn's disease: evidence for a chemokine mediated retention mechanism. Gut 55: 220-227.
27. Pickens SR, Chamberlain ND, Volin MV, Pope RM, Mandelin AM, et al. (2011) Characterization of CCL19 and CCL21 in rheumatoid arthritis. Arthritis Rheum 63: 914-922.
28. Damas JK, Smith C, Oie E, Fevang B, Halvorsen B, et al. (2007) Enhanced expression of the homeostatic chemokines CCL19 and CCL21 in clinical and experimental atherosclerosis: possible pathogenic role in plaque destabilization. Arterioscler Thromb Vasc Biol 27: 614-620.